TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04481204
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04481204
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04481204
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04481204
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04481204
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04771299
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
Study: NCT05801146
Drug: Botulinum Toxin Type A Injection [HG102]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Single administration, Day 0, 20 units
Study: NCT05801146
Drug: Botulinum Toxin Type A Injection [Botox]
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Single administration, Day 0, 20 units
Study: NCT00004573
Drug: ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04521946
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04521946
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04521946
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04521946
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT04521946
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04521946
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06514274
Drug: Berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 500 mg, twice daily for 14 days
Study: NCT06514274
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 20 mg, twice daily for 14 days
Study: NCT01410500
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
Study: NCT06514274
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000mg, twice daily for 14 days.
Study: NCT06514274
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth 220mg, twice daily for 14 days.
Study: NCT06514274
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 10mg, twice daily for 14 days.
Study: NCT05739006
Drug: BCD-201
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 8 treatment cycles
Study: NCT05739006
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: up to 8 treatment cycles
Study: NCT05891080
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days.
Study: NCT05891080
Drug: JS004
Normalized name: Immunoglobulin g4, anti-(human b and t lymphocyte attenuator (btla)) (human-mus musculus monoclonal js004 .gamma.4-chain), disulfide with human-mus musculus monoclonal js004 .kappa.-chain, dimer
DrugBank: Tifcemalimab (DB18914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days.
Study: NCT05891080
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days.
Study: NCT05891080
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days.
Study: NCT05891080
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days.
Study: NCT05533294
Drug: ARO-RAGE Injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARO-RAGE injection for sc administration
Study: NCT05719805
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05740956
Drug: HS-10502
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
Study: NCT05279924
Drug: Prophylaxis with Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
Study: NCT05503355
Drug: venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used
Study: NCT04601532
Drug: Silver Sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
Study: NCT05037695
Drug: empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: empagliflozin 25mg - daily
Study: NCT05546658
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin administration under supportive conditions
Study: NCT06658938
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14
Study: NCT06659250
Drug: PF-06414300
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral ascending doses.
Study: NCT06662396
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Extended-Release Capsule
Study: NCT06658977
Drug: Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One Triumeq tablet per day
Study: NCT00002412
Drug: Emivirine
Normalized name: Emivirine
DrugBank: Emivirine (DB08188)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002412
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002412
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002412
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06057935
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered intravenously
Study: NCT06057935
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered intravenously
Study: NCT06057935
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Possible substitution with carboplatin based on clinician discretion
Study: NCT06034873
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
Study: NCT06092216
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11.
Study: NCT03631771
Drug: Iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol administered intravascularly
Study: NCT03631771
Drug: Iodixanol
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol administered intravascularly
Study: NCT03631771
Drug: Iopromide
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopromide administered intravascularly
Study: NCT03631771
Drug: Ioversol
Normalized name: Ioversol
DrugBank: Ioversol (DB09134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ioversol administered intravascularly
Study: NCT03720626
Drug: crizanlizumab
Normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV formulation with 30 min infusion, 5mg/kg dosage
Study: NCT06304181
Drug: Paracetamol and Mannitol Injection
Normalized name: codeine and paracetamol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol and Mannitol Injection 500mg
Study: NCT06304181
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 40mg of parecoxib
Study: NCT04343170
Drug: ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
Study: NCT04904276
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib disodium
Study: NCT04723472
Drug: Cefuroxime containing bismuth quadruple treatment
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days.
Study: NCT04723472
Drug: Classic bismuth quadruple treatment
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days.
Study: NCT00000805
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05725005
Drug: ASN51
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASN51 formulation for oral capsule
Study: NCT05980416
Drug: EO-3021
Normalized name: EO-3021
DrugBank: EO-3021 (DB18358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Claudin 18.2 antibody drug conjugate
Study: NCT05611645
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
Study: NCT06544785
Drug: Zanubrutinib Oral Product
Normalized name: zanubrutinib Oral Product
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day.
Study: NCT06544785
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg).
Study: NCT04741789
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet for oral use, dose Up to 400mg, twice daily
Study: NCT05170724
Drug: Remibrutinib
Normalized name: Remibrutinib
DrugBank: Remibrutinib (DB16852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
Study: NCT04809766
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04809766
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05706623
Drug: Apraglutide
Normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of apraglutide 5mg.
Study: NCT05271253
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
Study: NCT05271253
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine is injected in the caudal epidural space
Study: NCT06552546
Drug: Icodextrin
Normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
Study: NCT04728360
Drug: Stelara (EU-sourced)
Normalized name: Stelara
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg/0.5 mL
Study: NCT04079231
Drug: Brolucizumab
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection
Study: NCT04079231
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection
Study: NCT04641728
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab 200 mg every three weeks (Q3W)
Study: NCT04641728
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: olaparib 300 mg twice daily (BID)
Study: NCT04784052
Drug: JSP191
Normalized name: IMMUNOGLOBULIN G1 (297-GLUTAMINE), ANTI-(HUMAN C-KIT RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .KAPPA.-CHAIN, DIMER
DrugBank: Briquilimab (DB18136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose at start of conditioning
Study: NCT04784052
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 consecutive daily doses of fludarabine will be given by IV during conditioning
Study: NCT04784052
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 dose of rituximab will be given at the end of conditioning
Study: NCT04747054
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
Study: NCT06007911
Drug: Navitoclax Dose Level -1
Normalized name: peanut allergenic extract
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg by mouth on days 1-7.
Study: NCT06007911
Drug: Navitoclax Dose Level 0
Normalized name: peanut allergenic extract
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg by mouth on days 1-10.
Study: NCT06489184
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients with treatment naive or R/R CLL who treatment with Zanubrutinib
Study: NCT06007911
Drug: Navitoclax Dose Level 1
Normalized name: peanut allergenic extract
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg by mouth on days 1-10.
Study: NCT05522582
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
Study: NCT06007911
Drug: Navitoclax Dose Level 2
Normalized name: peanut allergenic extract
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg by mouth on days 1-10.
Study: NCT06007911
Drug: Venetoclax Dose Level -1
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg by mouth on days 1-7.
Study: NCT04699838
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin
Study: NCT04699838
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin
Study: NCT04699838
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide
Study: NCT04699838
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab
Study: NCT04699838
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib
Study: NCT06517069
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
Study: NCT06007911
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/m\^2 intravenously days 1-5.
Study: NCT06007911
Drug: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/m\^2 subcutaneous days 1-10.
Study: NCT05238207
Drug: BBI-001
Normalized name: BBIBP-CorV
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
Study: NCT05961111
Drug: Recombinant oncolytic herpes simplex virus type 1 (R130)
Normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT05175430
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
Study: NCT05175430
Drug: Lysergic Acid Diethylamide
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.